Product Information
TOPIRAMATE ER 100 MG CAPSULE is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $10.6752 per EA under NDC 68382076906. Its NADAC has been published 185 times since Mar 22, 2023.
FDA first approved this application on Nov 24, 2017. Its Orange Book therapeutic-equivalence code is AB1 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
100 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382076906
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA207382FDA Approved
11/24/2017
TE Code
AB1
On Market Since
9/10/2024
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 100 MG CAPSULE has been published 185 times since Mar 22, 2023, and over the history we have for it it has declined 57.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.6752 per EA |
|---|---|
| All-time high | $25.3872 (Jul 12, 2023) |
| All-time low | $10.2003 (Aug 19, 2026) |
| 52-week high | $13.4017 |
| 52-week low | $10.2003 |
| Median price | $13.7322 |
| Average price | $15.5273 |
| Largest weekly change | +38.3% (Aug 21, 2024) |
| Weeks tracked | 185 |
| Tracking since | Mar 22, 2023 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 49% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 100 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 100 MG CAPSULE, manufactured by Zydus Pharmaceuticals (USA) Inc., is $10.6752 per EA (NDC 68382076906), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 100 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 100 MG CAPSULE has declined 57.2%. It has been tracked across 185 weekly CMS publications since Mar 22, 2023.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 100 MG CAPSULE?
Since Mar 22, 2023, the NADAC for TOPIRAMATE ER 100 MG CAPSULE has ranged from a low of $10.2003 (Aug 19, 2026) to a high of $25.3872 (Jul 12, 2023), with a median of $13.7322 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 100 MG CAPSULE?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, TOPIRAMATE ER 100 MG SPRINK CAP, is $5.4921 per EA — about 49% below TOPIRAMATE ER 100 MG CAPSULE.
Who manufactures TOPIRAMATE ER 100 MG CAPSULE?
TOPIRAMATE ER 100 MG CAPSULE (NDC 68382076906) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.